Plain-English translation of NCT06378190 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1/2 — A combined trial that checks safety and dosing while also starting to look at whether the treatment works.
This trial is testing TranspoCART19, a new immunotherapy that uses your own T cells (a type of white blood cell) to fight back against B-cell lymphoma. Researchers take your T cells, modify them in the lab to recognize and attack cancer cells, then give them back to you. The trial is designed to see if this approach is safe and how well it works for patients whose lymphoma has returned or didn't respond to standard treatments.
Many patients with relapsed or refractory B-cell lymphoma have limited options and poor outcomes with current treatments. This trial exists to test whether this new treatment could offer hope to patients who have exhausted other approved therapies.
You likely qualify if…
You likely don't qualify if…
If you enroll, doctors will first collect some of your T cells through a procedure called lymphapheresis (similar to donating blood). Your cells will be sent to a lab where they are genetically modified and expanded over several weeks. Once ready, you will receive an infusion of your modified cells back into your body. The trial has two phases: first, doctors test different doses to find the safest level, then more patients receive the optimal dose to evaluate how well it works.
AI-generated summary from trial data · Jun 12, 2026 · Not medical advice
Spain